Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-5 phase 3 trial of elranatamab alone or with daratumumab versus daratumumab + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
CTR20221192Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Jul 2022; status: active.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20221192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221192.